Use of erythropoietin for treating anemia of chronic kidney disease in a hospitalized pediatric population: MUE

Loading...
Thumbnail Image
Issue Date
2012-04-18
Embargo End Date
Authors
Dowis, Sileen
Finkeldei, Leah
Advisor
Hale, LaDonna S.
Bunton, Patricia A.
Citation

Sileen Dowis and Leah Finkeldei. (2012). Use of Erythropoietin for Treating Anemia of Chronic Kidney Disease in a Hospitalized Pediatric Population: MUE. -- In Proceedings: 8th Annual Symposium: Graduate Research and Scholarly Projects. Wichita, KS: Wichita State University, p.69

Abstract

Background: Patients with anemia of chronic kidney disease (CKD) lack the ability to produce erythropoietin causing a deficiency of red blood cells. Erythropoietin-stimulating agents (ESAs) are recommended by the National Kidney Foundation to treat anemia of CKD in adults; however, only recently have guidelines included pediatric dosing. Purpose: Determine if ESAs are being used appropriately in hospitalized children with anemia of CKD in accordance with guidelines from the National Kidney Foundation. Methods: This retrospective, non-interventional, cross-sectional medication use evaluation included all children <18 years old with anemia of CKD admitted to a large, tertiary-care hospital in 2010 (n=10). Results: Dosage reduction followed elevated hemoglobin levels 87% (13/15) of the time. Compliance was 100% for iron supplementation, laboratory monitoring, and route of administration. Conclusion: In children with CKD, ESA is being dosed and monitored at an acceptable rate of compliance in accordance with current national guidelines.

Table of Content
Description
Paper presented to the 8th Annual Symposium on Graduate Research and Scholarly Projects (GRASP) held at the Marcus Welcome Center, Wichita State University, April 18, 2012.
Research completed at the Department of Physician Assistant, College of Health Professions
publication.page.dc.relation.uri
DOI